Deutsch 
Test-Category
ELISA
Pack size
96 Tests
Standard concentrations included in the kit
0.1-2.0 µmol/l
Possible sample matrix and volumes
| EDTA plasma | 50 µl |
| Serum | 50 µl |
| Citrate plasma | 50 µl |
Incubation periods
Indications
Regulatory Status
For further information please contact www.neuroimmun.com
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, an enzyme that catalyses the production of nitric oxide from the amino acid arginine. Nitric oxide (NO) is one of the major endothelium-derived vasoactive mediators and is involved in the modulation of the blood flow and the blood pressure. Even small changes of the ADMA concentration alter vascular NO production, vascular tone, and systemic vascular resistence. Because of these properties NO has also been described as an "endogenous anti-atherosclerotic molecule".
Elevated ADMA concentrations are found in patients with diabetes mellitus, hyperchoesterolemia, hypertension, pulmonary hypertension, peripheral arterial disease, chronic renal failure, preeclampsia or erectile dysfunction.
ADMA was found to predict cardiovascular risk independently of other variables. It has thus been concluded that ADMA is a novel cardiovascular risk factor.
